Iceland vs Sierra Leone: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Iceland
92.0%
in 2025
Sierra Leone
93.0%
in 2025
Iceland rank
54th
Sierra Leone rank
51st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Iceland
- Sierra Leone
How they compare
Sierra Leone currently reports 93.0% against 92.0% in Iceland, a difference of 1.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Sierra Leone ahead.
Iceland ranks 54th and Sierra Leone ranks 51st of 192 countries.
Sierra Leone has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 71.6% | 78.8% | 7.2% | Sierra Leone |
| 2020s | 91.0% | 92.2% | 1.2% | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Iceland or Sierra Leone?
- Sierra Leone, at 93.0% against 92.0% in Iceland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Iceland and Sierra Leone?
- 1.0%, with Sierra Leone ahead.
- How many years of comparable data are there for Iceland and Sierra Leone?
- 18 years are reported by both, from 2008 to 2025.
- How do Iceland and Sierra Leone rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Iceland ranks 54th and Sierra Leone ranks 51st of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.